Welcome to our dedicated page for IDEXX LABORATORIES /DE SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEXX LABORATORIES /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEXX LABORATORIES /DE's regulatory disclosures and financial reporting.
IDEXX LABORATORIES INC /DE (IDXX) reported insider equity activity by Andrew Emerson, EVP, CFO and Treasurer. On August 20, 2026, he exercised an Incentive Stock Option to acquire 265 shares of common stock at an exercise price of $178.26 per share, reducing the option balance to 925 options expiring February 13, 2028. In connection with this exercise, 86 shares of common stock were delivered or withheld to cover the exercise price or tax liability. The filing notes that his common stock holdings include 20 shares purchased under the Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026.
IDEXX Laboratories, Inc. reported Q2 2026 total revenue of $1,216,585 (in thousands), up from $1,109,457, with net income of $338,412 and diluted EPS of $4.27, both higher than a year earlier. For the first six months, revenue reached $2,357,405 (in thousands) and net income $616,858.
Growth was led by the Companion Animal Group, with Q2 segment revenue of $1,118,236 (in thousands); Water and LPD also increased. Operating cash flow for the six months rose to $613,410 (in thousands), funding $703,732 (in thousands) of share repurchases while cash increased to $196,933 (in thousands).
The balance sheet shows total assets of $3,442,335 (in thousands) and borrowings of $519,000 (in thousands) under a $1.25 billion Credit Facility, with covenant compliance and $729.2 million of remaining availability. Customer commitment arrangements support estimated future revenues of approximately $5.3 billion over several years.
IDEXX Laboratories reported strong second‑quarter 2026 results, with revenue of $1,217 million, up 10% as reported and 9% organic versus the prior year. Diluted EPS was $4.27, an 18% increase, while comparable EPS grew 15% to $4.07. Gross margin reached 64.0% and operating margin 35.0%, both expanding 140 basis points year over year.
Growth was broad-based: Companion Animal Group revenue rose 9% as reported and 8.7% organic, driven by 11.0% reported and 10.3% organic growth in CAG Diagnostics recurring revenue, while Water revenue increased 14.8% reported and 13.0% organic and LPD revenue grew 10.8% reported and 9.0% organic.
The company raised its 2026 outlook, guiding revenue to $4,700–$4,745 million with 9.1%–10.3% reported growth and 8.5%–9.7% organic growth. It now expects operating margin of 32.3%–32.5% and EPS of $14.69–$14.94, implying 12%–14% reported and 13%–15% comparable EPS growth for the year.
IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units of common stock on July 30, 2026 under the company’s Director Deferred Compensation Plan. The grant represents $27,280.22 of deferred cash fees, converted at a closing share price of $558.80 per unit. Each unit equals one IDEXX common share, vests immediately, and will be paid in stock after his board service ends or on other preset dates allowed by the plan.
Executive Vice President George Fennell of IDEXX Laboratories reported routine equity compensation activity involving restricted stock units that vested on June 1, 2026. He acquired 639 shares of common stock through the conversion of restricted stock units, while 284 shares were disposed of to cover tax obligations. After these transactions, he directly holds 10,433 shares of common stock, reflecting a net increase in his equity position.
IDXX filed a Form 144 reporting a proposed sale of Common Stock through Goldman Sachs & Co. LLC. The filing lists multiple lots of Restricted Stock Units acquired as compensation on 05/11/2022, 05/11/2023, 05/06/2024, 05/06/2025, and 05/07/2026 with indicated share counts.
IDEXX Laboratories, Inc. reported that shareholders approved key governance changes at the 2026 annual meeting. Amendments to the Amended and Restated Certificate of Incorporation will declassify the Board over three years and move to annual elections for all directors beginning with the 2029 annual meeting.
Shareholders also approved giving investors who own at least 25% of the company’s stock continuously for at least one year the right to require the company to call a special shareholder meeting, subject to conditions in the By-Laws. Three Class II directors were elected through 2029, PricewaterhouseCoopers LLP was ratified as auditor, executive pay received advisory approval, and a separate shareholder proposal on special meeting rights was not approved.
IDEXX Laboratories director Sophie V. Vandebroek reported equity compensation grants in the form of restricted stock units and stock options. She received 234 restricted stock units, each representing one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share. Both the units and options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever comes earlier.
IDEXX Laboratories director Sam Samad received new equity awards as part of his board compensation. On May 12, 2026, he was granted 234 deferred stock units, each representing a right to one share of common stock, bringing his deferred stock unit balance to 1,354 units. He also received a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share, with 525 options reported as held after the grant. Both the option and deferred stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs first. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Karen Peacock reported equity compensation awards. She received 234 deferred stock units and a non-qualified stock option covering 525 shares of common stock, both recorded as grants, not open-market purchases.
The stock option has an exercise price of $533.92 per share and expires in May 2036. Both the option and the deferred stock units vest in a single installment on the earlier of one year from grant or the 2027 annual meeting of shareholders. The deferred stock units are payable in common stock after her resignation from the board.